Data from Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study
Khoan Vu(University of California, San Francisco), Weiyun Z. Ai(City College of San Francisco), Basem M. William, Pamela Heeter(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Pierluigi Porcu(Thomas Jefferson University), Wade L. Berry(University of California, Los Angeles), Charalambos Andreadis(University of California, San Francisco), Chi-Heng Wu(National Taiwan University), Aaron Zhan(University of California, San Francisco), Frank McCormick(Frederick National Laboratory for Cancer Research), Laura B. Pincus(University of California, San Francisco), Erika Cavallone(University of California, San Francisco), Chen‐Yen Yang(University of California, San Francisco), Jonathan E. Brammer(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Lawrence K. Kaplan(University of California, San Francisco), Matthew J. Wieduwilt(Atrium Health Wake Forest Baptist)
Cited by 0
Related Papers
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655